Lundbeck Partners with DCAI to Leverage Gefion AI Supercomputer for Drug Discovery
H. Lundbeck A/S, a global leader in brain health, has announced a strategic agreement with the Danish Centre for AI Innovation (DCAI), the organization responsible for operating Gefion, Denmark’s AI supercomputer. Lundbeck is one of the first pharmaceutical companies to utilize Gefion’s computational power to advance drug discovery and development in the field of neurological and psychiatric disorders.




